Cyclosporine, a drug used in immunosuppression protocols for hematopoietic stem cell transplantation that has a narrow therapeutic index, may cause various adverse reactions, including nephrotoxicity. This has a direct clinical impact on the patient. This study aimsto summarize available evidence in the scientific literature on the use of cyclosporine inrespect to its risk factor for the development of nephrotoxicity in patients submitted to hematopoietic stem cell transplantation. A systematic review was made with the following electronic databases: PubMed, Web of Science, Embase, Scopus, CINAHL, LILACS, SciELO and Cochrane BVS. The keywords used were: “bone marrow transplantation” OR “stem cell transplantation” OR “grafting, bone marrow” AND cyclosporine OR cyclosporin OR “risk factors” AND “acute kidney injury” OR “acute kidney injuries” OR “acute renal failure” OR “acuterenal failures” OR “nephrotoxicity”. The level of scientific evidence of the studies was classified according to the Oxford Centre for Evidence Based Medicine. The final sample was composed of 19 studies, most of which (89.5%) had an observational design, evidence level 2B and pointed to an incidence of nephrotoxicity above 30%. The available evidence, considered as good quality and appropriate for the analyzed event, indicates that cyclosporinere presents a risk factor for the occurrence of nephrotoxicity, particularly when combinedwith amphotericin B or aminoglycosides, agents commonly used in hematopoietic stem cell transplantation recipients.
da Silva, J. B., Lima, M. H. de M., & Secoli, S. R. (2014, September 1). Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: A systematic review. Revista Brasileira de Hematologia e Hemoterapia. Sociedade Brasileira de Hematologia e Hemoterapia. https://doi.org/10.1016/j.bjhh.2014.03.010